Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 10/20 | 0.49 |
| ▸ | CA2 | P00918 | 4/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | SMURF1 | Q9HCE7 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13158458 | 0.91 | PTGS2 (0.52) | PTGS2CA2CA1TP53CA9 | |
| SCHEMBL13158427 | 0.88 | PTGS2 (0.49) | PTGS2CA2CA1TP53CA9 | |
| SCHEMBL13158460 | 0.88 | RAB9A (0.53) | PTGS2CA2CA1TP53RIPK1 | |
| SCHEMBL13158422 | 0.86 | TP53 (0.52) | PTGS2CA2CA1TP53CA9 | |
| SCHEMBL13158456 | 0.85 | PTGS2 (0.46) | PTGS2CA2CA1TP53CA9 | |
| SCHEMBL3105762 | 0.85 | PTGS2 (0.46) | PTGS2CA2CA1TP53RIPK1 | |
| SCHEMBL13158443 | 0.85 | HPGD (0.49) | PTGS2CA2CA1TP53RIPK1 | |
| SCHEMBL13158464 | 0.84 | PTGS2 (0.46) | PTGS2CA2CA1TP53RIPK1 | |
| SCHEMBL13158428 | 0.84 | PTGS2 (0.46) | PTGS2CA2CA1TP53RIPK1 | |
| SCHEMBL3108824 | 0.83 | ATM (0.41) | RIPK1RAB9ANPC1HPGDMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7803822-B2 | Triazole derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-28 | — | — | US | disclosed |
| US-20090105253-A1 | Triazole Derivative and Use Thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105253-A1 | Triazole Derivative and Use Thereof | F2R, HRH4, F2RL3 | PTGS2 1750/4885CA2 3067/4885CA1 3371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.